Literature DB >> 22567186

Identification of cellular genes showing differential expression associated with hepatitis B virus infection.

Yasuo Fukuhara1, Takeshi Suda, Makoto Kobayashi, Yasushi Tamura, Masato Igarashi, Nobuo Waguri, Hirokazu Kawai, Yutaka Aoyagi.   

Abstract

AIM: To investigate the impact of hepatitis B virus (HBV) infection on cellular gene expression, by conducting both in vitro and in vivo studies.
METHODS: Knockdown of HBV was targeted by stable expression of short hairpin RNA (shRNA) in huH-1 cells. Cellular gene expression was compared using a human 30K cDNA microarray in the cells and quantified by real-time reverse transcription-polymerase chain reaction (RT-PCR) (qRT-PCR) in the cells, hepatocellular carcinoma (HCC) and surrounding non-cancerous liver tissues (SL).
RESULTS: The expressions of HBsAg and HBx protein were markedly suppressed in the cells and in HBx transgenic mouse liver, respectively, after introduction of shRNA. Of the 30K genes studied, 135 and 103 genes were identified as being down- and up-regulated, respectively, by at least twofold in the knockdown cells. Functional annotation revealed that 85 and 62 genes were classified into four up-regulated and five down-regulated functional categories, respectively. When gene expression levels were compared between HCC and SL, eight candidate genes that were confirmed to be up- or down-regulated in the knockdown cells by both microarray and qRT-PCR analyses were not expressed as expected from HBV reduction in HCC, but had similar expression patterns in HBV- and hepatitis C virus-associated cases. In contrast, among the eight genes, only APM2 was constantly repressed in HBV non-associated tissues irrespective of HCC or SL.
CONCLUSION: The signature of cellular gene expression should provide new information regarding the pathophysiological mechanisms of persistent hepatitis and hepatocarcinogenesis that are associated with HBV infection.

Entities:  

Keywords:  Adipose most abundant 2; Differential gene expression; Gene expression signature; Hepatitis B virus; Hepatocellular carcinoma

Year:  2012        PMID: 22567186      PMCID: PMC3345538          DOI: 10.4254/wjh.v4.i4.139

Source DB:  PubMed          Journal:  World J Hepatol


  37 in total

1.  Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification.

Authors:  Itai Yanai; Hila Benjamin; Michael Shmoish; Vered Chalifa-Caspi; Maxim Shklar; Ron Ophir; Arren Bar-Even; Shirley Horn-Saban; Marilyn Safran; Eytan Domany; Doron Lancet; Orit Shmueli
Journal:  Bioinformatics       Date:  2004-09-23       Impact factor: 6.937

2.  Expression profile of nine novel genes differentially expressed in hepatitis B virus-associated hepatocellular carcinomas.

Authors:  M Y Kim; E Park; J H Park; D H Park; W S Moon; B H Cho; H S Shin; D G Kim
Journal:  Oncogene       Date:  2001-07-27       Impact factor: 9.867

3.  Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells.

Authors:  David Wai Chan; Irene Oi-lin Ng
Journal:  J Pathol       Date:  2006-02       Impact factor: 7.996

4.  APM2 is a novel mediator of cisplatin resistance in a variety of cancer cell types regardless of p53 or MMR status.

Authors:  Bradley J Scott; Sami Qutob; Qing Y Liu; Cheng E Ng
Journal:  Int J Cancer       Date:  2009-09-01       Impact factor: 7.396

5.  Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection.

Authors:  Ramamurthy Narayan; Bevin Gangadharan; Olivier Hantz; Robin Antrobus; Angela García; Raymond A Dwek; Nicole Zitzmann
Journal:  J Proteome Res       Date:  2009-01       Impact factor: 4.466

6.  Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis.

Authors:  Norio Iizuka; Masaaki Oka; Hisafumi Yamada-Okabe; Naohide Mori; Takao Tamesa; Toshimasa Okada; Norikazu Takemoto; Kiichiro Hashimoto; Akira Tangoku; Kenji Hamada; Hironobu Nakayama; Takanobu Miyamoto; Shunji Uchimura; Yoshihiko Hamamoto
Journal:  Oncogene       Date:  2003-05-15       Impact factor: 9.867

7.  Side effects of long-term oral antiviral therapy for hepatitis B.

Authors:  Robert J Fontana
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

8.  Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers.

Authors:  Masamitsu Onda; Mitsuru Emi; Hisaki Nagai; Takemitsu Nagahata; Kouji Tsumagari; Takashi Fujimoto; Futoshi Akiyama; Goi Sakamoto; Masujirou Makita; Fujio Kasumi; Yoshio Miki; Toshihiro Tanaka; Tatsuhiko Tsunoda; Yusuke Nakamura
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-03       Impact factor: 4.553

9.  Hepatitis B virus-mediated changes of apolipoprotein mRNA abundance in cultured hepatoma cells.

Authors:  Pamela A Norton; Qiaoke Gong; Anand S Mehta; Xuanyong Lu; Timothy M Block
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

10.  Interferon can block telomere erosion and in rare cases result in hepatocellular carcinoma development with telomeric repeat binding factor 1 overexpression in chronic hepatitis C.

Authors:  Masato Igarashi; Takeshi Suda; Hidenori Hara; Mitsuhiro Takimoto; Minoru Nomoto; Toru Takahashi; Shogo Okoshi; Hirokazu Kawai; Yusaku Mita; Nobuo Waguri; Yutaka Aoyagi
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

View more
  2 in total

Review 1.  What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

2.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Fang Xu; Xiaohao Shi; Yue Wang; Linhong Deng
Journal:  Cytotechnology       Date:  2014-07-08       Impact factor: 2.058

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.